Albert David Ltd (ALBERTDAVD) AI Stock Analysis

• Market Cap: ₹4.45B
• Dividend Yield: 0.64%
• Average Volume (3M): 307.00
• Price to Earnings (P/E): 70.7
• Beta (1Y): 0.98
• Revenue Growth: -9.14%
• EPS Growth: -91.11%
• Country: IN
• Employees: 1,497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.91
• Shares Outstanding: 5,707,162
• 10 Day Avg. Volume: 253
• 30 Day Avg. Volume: 307
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹964.00
• Price Target Upside: 23.65% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹964.00 ▲(23.65% Upside)

Albert David Ltd's stock score reflects a stable balance sheet with low debt but is hampered by declining revenue and profitability, along with negative cash flow trends. Technical indicators are mixed, and the stock appears overvalued with a high P/E ratio and low dividend yield. These factors contribute to a cautious outlook.

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.

How the Company Makes Money

Albert David Ltd. generates revenue primarily through the sale of its pharmaceutical products, which include a variety of formulations and bulk drugs. The company's revenue streams include domestic sales within India and exports to international markets. Key products contributing to its revenue include intravenous fluids, therapeutic formulations, and herbal products. Additionally, the company may engage in strategic partnerships and collaborations to enhance its distribution network and market reach, further contributing to its earnings.

Albert David Ltd Financial Statement Overview

Summary

Albert David Ltd demonstrates strength in its balance sheet with low leverage and strong equity. However, declining revenue and profitability, along with negative operating and free cash flows, are critical challenges. The company must address these issues to sustain long-term growth and financial health.

Income Statement

Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.

Balance Sheet

The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.

Cash Flow

Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.46B	3.46B	3.60B	3.42B	3.12B	2.46B
Gross Profit	2.29B	2.29B	2.32B	2.18B	1.95B	1.58B
EBITDA	30.26M	30.26M	1.05B	598.68M	567.76M	364.59M
Net Income	172.01M	172.01M	754.20M	361.75M	352.58M	221.43M
Balance Sheet
Total Assets	5.11B	5.11B	4.98B	4.23B	4.03B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.44B	2.44B	2.85B	2.08B	1.75B	1.49B
Total Debt	123.17M	123.17M	33.24M	53.18M	56.62M	16.19M
Total Liabilities	1.19B	1.19B	1.15B	1.12B	1.23B	970.20M
Stockholders Equity	3.92B	3.92B	3.83B	3.12B	2.79B	2.44B
Cash Flow
Free Cash Flow	0.00	-432.92M	346.28M	52.78M	292.83M	349.79M
Operating Cash Flow	0.00	-284.36M	455.02M	105.15M	403.65M	366.11M
Investing Cash Flow	0.00	233.01M	-391.08M	-49.95M	-396.97M	-366.84M
Financing Cash Flow	0.00	1.10M	-82.70M	-63.62M	-48.80M	-17.05M

Albert David Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 779.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 779.65 is below the 20-day moving average (MA) of 801.75, below the 50-day MA of 828.97, and below the 200-day MA of 939.49, indicating a bearish trend. The MACD of -8.49 indicates Positive momentum. The RSI at 30.04 is Neutral, neither overbought nor oversold. The STOCH value of 10.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALBERTDAVD	65 Neutral	₹4.45B	70.70	―	0.64%	-9.14%	-91.11%
LYKALABS	58 Neutral	₹3.39B	45.17	7.74%	―	19.40%	1286.88%
ZIMLAB	54 Neutral	₹3.57B	38.06	4.82%	―	-3.36%	-47.58%
VIKASLIFE	47 Neutral	₹4.11B	-36.47	-2.00%	―	9.42%	-12220.00%
NECLIFE	43 Neutral	₹3.26B	-1.81	-11.89%	―	-3.41%	-3028.44%
BROOKS	42 Neutral	₹4.03B	313.47	-10.16%	―	10.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%